Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 14, 2005. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory notification of share transactions and does not contain financial performance data.
Material Changes
The filing details specific share transfers from the GlaxoSmithKline Employee Trust ("GSK Trust") to plan participants:
- October 13, 2005: Transfer of 8,306 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
- October 14, 2005: Transfer of 7,393 Ordinary Shares to participants in the GlaxoSmithKline Restricted Share Plan.
These transactions were advised to the Company on October 14, 2005.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that the GSK Trust is a discretionary trust for current and former employees, and that three directors (Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop) hold interests in the trust shares similarly to other employees.
Investor Verification Checklist
- Verify the total number of shares transferred (15,699 total) against the company's employee benefit plan disclosures.
- Confirm the specific plans involved: SmithKline Beecham Employee Share Option Plan 1991 and GlaxoSmithKline Restricted Share Plan.
- Review the status of the GSK Trust as a discretionary trust for employee beneficiaries.
- Note that this filing does not reflect operational or financial performance for the period.